TScan Therapeutics, Inc.
TCRX · Nasdaq · United States
Share price · TCRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TCRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Oct 2026-17.6%
Nothing announced by TCRX that day or the session before.
- 2 Sep 2026-42.8%
- 19 Aug 2026-9.1%
- Day beforeTermination of a material agreement
- 9 Jul 2026-15.9%
Nothing announced by TCRX that day or the session before.
- 8 Jul 2026+17.8%
Nothing announced by TCRX that day or the session before.
- 1 Jul 2026+9.2%
Nothing announced by TCRX that day or the session before.
- 26 Jun 2026+15.3%
Nothing announced by TCRX that day or the session before.
- 22 Jun 2026-6.0%
- 16 Jun 2026-10.8%
Nothing announced by TCRX that day or the session before.
- 21 Apr 2026-11.2%
Nothing announced by TCRX that day or the session before.
Share of unusual movement by asset
For each asset, the share of TCRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
TSC-101events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 32% |
| Sessions with no dated event | — | 67% |
Assets
(2 total)
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0.6M | $25M | $78M | $33M-$27M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.1M | $23M | $105M | $30M-$28M operating cash flow | report ↗ |
| 2026-Q1 | $1.0M | $22M | $133M | $29M-$24M operating cash flow | report ↗ |
| 2025-Q3 | $2.5M | $32M | $175M+ $15M short-term inv. | $36M-$32M operating cash flow | report ↗ |
| 2025-Q2 | $3.1M | $33M | $174M+ $49M short-term inv. | $37M-$33M operating cash flow | report ↗ |
| 2025-Q1 | $2.2M | $30M | $159M+ $98M short-term inv. | $34M-$38M operating cash flow | report ↗ |
| 2024-Q3 | $1.1M | $26M | $138M+ $138M short-term inv. | $30M-$28M operating cash flow | report ↗ |
| 2024-Q2 | $0.5M | $27M | $247M+ $56M short-term inv. | $32M-$26M operating cash flow | report ↗ |
| 2024-Q1 | $0.6M | $25M | $146M+ $22M short-term inv. | $30M-$29M operating cash flow | report ↗ |
| 2023-Q3 | $3.9M | $23M | $160M+ $60M short-term inv. | $23M$8.0M operating cash flow | report ↗ |
| 2023-Q2 | $3.1M | $21M | $214M | $24M-$22M operating cash flow | report ↗ |
| 2023-Q1 | $6.8M | $22M | $101M | $23M-$24M operating cash flow | report ↗ |
| 2022-Q3 | $3.4M | $15M | $142M | $16M-$17M operating cash flow | report ↗ |
| 2022-Q2 | $4.1M | $14M | $131M | $15M-$13M operating cash flow | report ↗ |
| 2022-Q1 | $3.0M | $15M | $146M | $16M-$20M operating cash flow | report ↗ |
| 2021-Q3 | $2.4M | $14M | $183M | $16M-$14M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $10M | $114M | $157M | $32M-$135M operating cash flow | report ↗ |
TScan Therapeutics reported full-year 2025 revenue of $10.33M, up 266.3% YoY, with R&D spend of $114.15M, up 6.3% YoY. Cash and equivalents stood at $157.44M, and the company reported a net loss of $129.77M.
TScan highlighted positive updated data from the ALLOHA Phase 1 heme trial, completed enrollment in Cohort C using its commercial-ready manufacturing process, and received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45. The company plans to share initial Cohort C data and launch a pivotal TSC-101 trial in the second quarter of 2026, initiate a Phase 1 study of the TSC-102 candidates in the second half of 2026, and discontinued its PLEXI-T solid tumor trial. Management expects existing cash to fund operations into the second half of 2027.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $2.8M | $107M | $184M+ $111M short-term inv. | $32M-$111M operating cash flow | report ↗ |
| 2023-FY | $21M | $88M | $138M+ $59M short-term inv. | $22M-$61M operating cash flow | report ↗ |
| 2022-FY | $14M | $60M | $125M | $17M-$67M operating cash flow | report ↗ |
| 2021-FY | $10M | $45M | $166M | $12M-$49M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($146K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-01 | ZDRAVESKI ZORAN · See Remarks | Award / grant | 300,000 | — | — | Form 4 |
| 2026-10-01 | MacBeath Gavin · director, Chief Executive Officer | Award / grant | 1,000,000 | — | — | Form 4 |
| 2026-05-20 | Klencke Barbara · director | Award / grant (derivative) | 67,000 | — | — | Form 4 |
| 2026-05-20 | Dorton Katina · director | Award / grant (derivative) | 67,000 | — | — | Form 4 |
| 2026-05-20 | Gruia Gabriela · director | Award / grant (derivative) | 67,000 | — | — | Form 4 |
| 2026-05-20 | Nicholson Garry A · director | Award / grant (derivative) | 67,000 | — | — | Form 4 |
| 2026-05-20 | Woods Keith · director | Award / grant (derivative) | 67,000 | — | — | Form 4 |
| 2026-05-20 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN · director; director; director; director; director; director | Award / grant (derivative) | 67,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 60 reporting institutions held 32.5M shares ($32.2M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 8,019,148 | $8.1M |
| 2 | BVF INC/IL | 5,564,290 | $5.6M |
| 3 | BAKER BROS. ADVISORS LP | 2,784,792 | $2.8M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,154,256 | $2.2M |
| 5 | BlackRock, Inc. | 1,840,952 | $1.9M |
| 6 | MILLENNIUM MANAGEMENT LLC | 1,460,285 | $1.5M |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1,364,783 | $1.4M |
| 8 | Deer Management Co. LLC | 1,245,504 | $1.3M |
| 9 | TWO SIGMA INVESTMENTS, LP | 1,209,009 | $1.2M |
| 10 | Aberdeen Group plc | 918,020 | $927K |
| 11 | JACOBS LEVY EQUITY MANAGEMENT, INC | 808,356 | $816K |
| 12 | DC Funds, LP | 630,000 | $630K |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 616,952 | $623K |
| 14 | D. E. Shaw & Co., Inc. | 319,587 | $323K |
| 15 | CITADEL ADVISORS LLC | 318,411 | $322K |